In this randomized trial, investigators sought to determine the effectiveness of high-dose dexamethasone vs conventional prednisone therapy in treatment-naïve patients with ITP. Results were presented at ASH 2017.

Ibrutinib — a Bruton tyrosine kinase inhibitor — is currently used among patients with WM who have previously received treatment. This prospective, phase 2 study sought to determine its efficacy as a first-line therapy in treatment-naive patients.

Young patients with chronic ITP may experience relapse within 5 years of completing therapy. In this study, investigators sought to determine if the 4R+3Dex regimen for chronic ITP would improve response rates in pediatric patients with the disease.

In this analysis, researchers measured the impact and effectiveness of supportive treatments for moderate to severe anemia in patients with lymphoma or multiple myeloma, based on patient-reported outcomes.

Indications for vemurafenib are expanded to include BRAF V600 mutation-positive Erdheim-Chester disease, an extremely rare non-Langerhans cell histiocytosis. FDA approval is based on results from the phase 2 VE-BASKET study.

Previous studies determined the effectiveness of 6 months of therapy with eltrombopag in patients with ITP. In this analysis, researchers extended 4 clinical trials to assess efficacy and safety of eltrombopag therapy for more than 6 months in patients with ITP.

Sinusoidal obstruction syndrome (or hepatic veno-occlusive disease), a complication observed in patients who undergo HSCT, is managed with defibrotide. In this study, investigators assessed its efficacy and patient response to therapy.

[Blood and Lymphatic Cancer: Targets and Therapy] Investigators conduct 4 case studies that illustrate a range of coagulation disorders that can develop in patients with leukemia to elucidate the rationale and process of specific treatment options.

This case of a 63-year-old African American male with a complicated history illustrates the need for a comprehensive risk assessment of thrombosis in patients with primary polycythemia vera, especially those with concomitant conditions that predispose to thrombosis.

A retrospective analysis of 28 studies determined that overall response rates for patients with ITP were similar treated with hydroxychloroquine, danazol, or dapsone in the second-line setting were similar.

Results of a retrospective single-center study showed that response to rituximab vs splenectomy as second-line therapy for steroid-refractory ITP was not significantly different between the 2 treatments.

Approximately 40% of ITP cases are caused by gram-negative H pylori infection; therefore, researchers sought to determine the effectiveness of infection eradication on platelet count in these patients.